Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:79-81.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.